MNOV
MediciNova, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.63
+0.62%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 920.5K | 409.7K | — | 1.0M | — |
| Cost of Revenue | 530.3K | 378.6K | — | — | — |
| Gross Profit | 390.2K | 31.1K | — | 1.0M | — |
| Operating Expenses | |||||
| R&D Expense | 1.3B | 7.2M | 7.2M | 5.7M | 9.1M |
| SG&A Expense | 1.6B | 6.2M | 5.5M | 5.2M | 5.5M |
| General & Admin Expense | 1.6B | 6.0M | 5.2M | 5.0M | 5.2M |
| Selling & Marketing Expense | 48.6K | 204.2K | 258.6K | 257.9K | 248.6K |
| Other Expenses | (2.8B) | (412.00) | (413.00) | (400.00) | 388.00 |
| Total Operating Expenses | 12.2M | 13.3M | 12.7M | 10.9M | 14.6M |
| Cost and Expenses | 12.8M | 13.7M | 12.7M | 10.9M | 14.6M |
| Operating Income (EBIT) | (11.9M) | (13.3M) | (12.7M) | (9.9M) | (14.6M) |
| Non-Operating | |||||
| Interest Income | 341.0M | 1.3M | 1.7M | 1.8M | 809.7K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 341.0M | 1.3M | 1.7M | 1.8M | 809.7K |
| Other Non-Op Income/Expense | 1.1M | 1.3M | 1.6M | 1.3M | 562.4K |
| Non-Operating Income (excl Interest) | (881.2K) | (1.3M) | (1.6M) | (1.3M) | (562.4K) |
| EBT (Pre-Tax Income) | (10.7M) | (12.0M) | (11.0M) | (8.6M) | (14.1M) |
| Income Tax Expense | 6.0K | 6.0K | 5.5K | 3.0K | 2.8K |
| Bottom Line | |||||
| Net Income | (10.8M) | (12.0M) | (11.0M) | (8.6M) | (14.1M) |
| Earnings from Cont. Ops | (10.8M) | (12.0M) | (11.0M) | (8.6M) | (14.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (10.8M) | (12.0M) | (11.0M) | (8.6M) | (14.1M) |
| Per Share | |||||
| Basic EPS | ($0.22) | ($0.24) | ($0.23) | ($0.17) | ($0.29) |
| Diluted EPS | ($0.22) | ($0.24) | ($0.23) | ($0.17) | ($0.29) |
| Revenue Per Share | $0.02 | $0.01 | $0.00 | $0.02 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 49.2M | 49.1M | 49.0M | 49.0M | 49.0M |
| Diluted Shares Outstanding | 49.2M | 49.1M | 49.0M | 49.0M | 49.0M |
| Profitability Metrics | |||||
| EBITDA | (11.0M) | (12.0M) | (11.0M) | (8.5M) | (14.0M) |
| D&A | (7.1K) | 20.1K | 21.1K | 20.3K | 17.7K |
| EBIT | (11.0M) | (12.0M) | (11.0M) | (8.6M) | (14.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026